ANO1: Anoctamin-1
Calcium-activated chloride channel (CaCC).
- Drugs that act on it: 1
- Approved: 1
- In phases 1 to 3: 0
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on ANO1, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
The landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Crofelemer | Approved | NAPO Pharmaceuticals | Small molecule | BlockerAnoctamin-1 blocker | 3 |
Open trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 3 in all, from ClinicalTrials.gov.| Safety and Efficacy of Crofelemer in Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC) | Crofelemer | Phase 2 | Recruiting | Napo Therapeutics, S.p.A. | Apr 1, 2025 |
| Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID) | Crofelemer | Phase 2 / Phase 3 | Active, not recruiting | Napo Pharmaceuticals, Inc. | Dec 6, 2024 |
| Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome | Crofelemer | Early phase 1 | Active, not recruiting | Jessica Sosio | Mar 22, 2024 |
Diseases most associated with it
Open Targets association score, 0 to 1; all associations- Moyamoya disease 7
- 0.58
- Diarrheal disease
- 0.54
- Abnormality of the skeletal system
- 0.54
- Diverticular disease
- 0.43
- Cholelithiasis
- 0.42
- Thrombophilia
- 0.38
- COVID-19
- 0.37
- Alcohol drinking
- 0.35
- Hypertensive disorder
- 0.35
- Intestinal dysmotility syndrome
- 0.34
- Female genital tract polyp
- 0.34
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2046267, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q5XXA6, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets